Claudin-6 Antibodies

Claudin-6 (CLDN6)

Plays a major role in tight junction-specific obliteration of the intercellular space. .

.

Gene Information

Human
Gene Name:	CLDN6
Uniprot:	P56747
Entrez:	9074

Family

Belongs to:
claudin family

Alternative Names

claudin 6; Claudin6; Claudin-6; CLDN6; Skullin 2; skullin

Molecular Weight

Mass (kDA):
23.292 kDA

Genomic Context

Human
Location:	16p13.3
Sequence:	16; NC_000016.10 (3014712..3018183, complement)

Tissue Specificity

Expressed in the liver, in peripheral blood mononuclear cells and hepatocarcinoma cell lines.

Subcellular Localizations

Cell junction, tight junction. Cell membrane; Multi-pass membrane protein.

Diseases

• Neoplasms
• Malignant Neoplasms
• Carcinoma
• Rhabdoid Tumor
• Esophageal Neoplasms
• Squamous Cell Carcinoma Of Esophagus
• Dehydration
• Neuroectodermal Tumors
• Cell Invasion
• Malignant Squamous Cell Neoplasm
• Brain Neoplasms
• Premature Birth
• Neoplasms, Neuroepithelial

• Stomach Neoplasms
• Malignant Neoplasm Of Breast
• Sarcoma
• Severe Combined Immunodeficiency
• Mammary Neoplasms
• Medulloblastoma
• Ependymal Tumor

Interacting Proteins

• TMEM179B

Pathways

• Localization
• Methylation
• Dna Methylation
• Transport
• Cell Proliferation
• Gene Silencing
• Aging
• Ion Transport
• Complement-dependent Cytotoxicity
• Blood Circulation

• Keratinocyte Differentiation
• Tight Junction Assembly
• Hair Cycle
• Anagen
• Antibody-dependent Cellular Cytotoxicity

PTMs

• Methylation
• Demethylation

• Phosphorylation
• Reduction

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CLDN6

Best Uses of the CLDN6 Marker

The CLDN6 Marker is useful in many oncological conditions and has many benefits. Here are some options for using the CLDN6 marker in your research. The diagnosis of cancer is made easier by the detection of CLDN6/Claudin 6. This article will show you how to identify antibodies that target this protein. The benefits of using the CLDN6 marker are also discussed.

Benefits of using the CLDN6 Marker in oncological diseases

Recent research has shown that patients with cancer can benefit from the CLDN6 Marker. CLDN6 expression levels were significantly correlated with tumor stage and pN categories in TNM classification. The OS in the positive group was also significantly higher than that in the negative group. The CLDN6 marker was also associated with the Lauren type of cancer and the intestinal type.

CLDN6 protein has been found to be highly expressed within cancer cells. However, the protein was not detected within normal tissues. Therefore, it was necessary for an assay to detect cancer cells in normal tissues and investigate their function. CLDN6 antibody detection was developed to detect changes of CLDN6. Its utility in the diagnosis and therapy of cancer is discussed in the following paragraphs.

Below are some advantages of the CLDN6Marker. CLDN6 Marker is best expressed on the skin of cancer cells. The CLDN6Marker is useful in clinical settings for oncological disorders such as pancreatic cancer, leukemia, and renal cell carcinoma. These diseases can be successfully treated by CLDN6 antibody therapy.

The CLDN6Marker is an important diagnostic tool. It is a tool that doctors use to distinguish cancer cells according to their CLDN6 gene expression levels. CLDN6 expression in gastric cancer tissues is low, but it is linked to age and lymphode metastasis. This is associated with poor prognosis. These preliminary results do not rule out the potential benefits of the CLDN6 Marker for oncological diseases.

The CLDN6 marker is highly specific for EpCAM- and CD45-positive cancer cells. It has been shown that it strongly correlates with cytotoxicity of human tumor cells. In a recent study, a CD8-TCR transduced T cell line showed specific cytotoxicity against A2/CLDN6-overexpressing cancer cells. Its expression levels were higher than those of the CD45+ cells.

CLDN6 can also be used in oncological disease treatment. The CLDN6 Gene is found in the plasma membrane of transfected tissues. To target the CLDN6 protein, you can use specific antibodies. Moreover, serum from mice is known to produce a hybridoma F3-6C3-H8 cell type. These findings demonstrate the utility and value of the CLDN6 marker in oncological disease.

Clinical trials have shown that CLDN6 CAR–T cells therapy is effective in treating ovarian tumors. Clinical trials are currently underway at multiple locations in Germany and the Netherlands for this treatment. These results are expected to be published later in this year. This is the first phase in clinical trials for CLDN6 targeted CAR-T cell therapy. These benefits will continue to be confirmed in cancer patients by further research.

Antibodies to CLDN6/Claudin6

Claudin-6, a member of the claudin proteins family, has 27 members. The claudin protein family plays a crucial role in cell to cell adhesion, tight joints, and tumor progression. Its diagnostic value, biological functions, and molecular signatures make it an effective marker for cancer. CLDN6 expression has been linked with many types and types of cancer, despite the variety of its function in human malignancies.

Boster Bio has an anti-Claudin-6 antibody that reacts with Mouse. It is available in PBS containing 0.09 percent sodium azide. The antibody was made from rabbits that were immunized using a synthetic peptide. The immunogen's length determines the cost. Alternatively, anti-Claudin-6 antibodies can be purchased separately. They are suitable for immunofluorescence labeling and Western blotting.

The results of the study suggest that antibodies to CLDN6/Claudin6 could be used as biomarkers in pancancer, including UCEC. However, further investigation in UCEC is needed to understand its role in tumor promotion and suppression. This work could also be used to integrate analyzing bases for molecular biological experiments and the development a targeted cancer therapy.

Boster Bio's ELISA kits can detect recombinant CLDN6/Claudin6 in many samples. Picokine (tm) high sensitivity ELISA platforms increases the sensitivity of picograms. Picokine(tm) ELISA kits can be validated on diverse samples, and images and validation procedures are available upon request. Supervision polymer-based secondary antibodies can save up to 30 minutes IHC Picoband's high-sensitivity and specific capabilities are complemented by the technical support provided by Sanbio, a BeNeLux distributor.

CLDN6 plays multiple functions in cancer. The expression of this protein has been linked to UCEC stage, tumor invasion and DSS. This research also indicates that CLDN6 has been linked with BMI, UCEC Stage, and menopause. CLDN6 levels are also linked to postmenopause status. Additionally, higher levels CLDN6 have been linked to a worse prognosis and a lower PFI.

Animal studies showed that the chimeric antigen HBcAg inhibited the growth and spread of melanoma cells. A recently developed nanoparticle vaccine using ferritin, a VLP consisting of 24 self-assembled subunits with a cage-like symmetry, is designed to display pathogenic-associated antigens. It was created using the SpyTag–SpyCatcher method. In addition, the ferritin nanoparticle vaccine induced highly potent MUC-1-specific antibodies and CTLs.

Detection of CLDN6/Claudin 6 in oncological diseases

While CLDN6/claudin 6 has been detected in oncological conditions, it has been shown that it is associated with PI3K/AKT activities in endometrial cells. The molecular mechanisms behind this association are not clear. However, ERa is thought to be a master transcription factor in endometrial carcinomas. This could lead to aberrant CLDN6 signaling.

Recent research has shown that CLDN6 expression in tumour tissues is consistently higher than in normal tissues. They speculate that these changes may suggest that CLDN6 is a new antigen or a therapeutic target in tumours. But, further research is needed in order to determine if this novel antigen is a viable treatment for cancer. Moreover, studies must be conducted to determine whether CLDN6 is a potential target for cancer.

It is important that CLDN6 expression is high in certain types of embryonic epithelial cell lines, but is absent in normal adult cells. It is believed that abnormal CLDN6 expression can lead to tumour progression and damage to TJs. CLDN6 also is highly expressed in various types and types of tumours, including seminomas or embryonal cancers. CLDN6 is also found in cancers such as breast, colon and liver.

Numerous studies have shown an association between CLDN6 expression and survival time. There is intratumoral heterogeneity also in CLDN6 gene expression. CLDN6-positive and CLDN6–negative subpopulations were found in human endometrial carcinoma tissues. This highlights the importance to carefully evaluate CLDN6 expression in small biopsy specimens.

It cannot be overemphasized how important it is for cancer cells to be able to detect CLDN6/Claudin 6. CSCs are associated with increased drug resistance. Therefore, it is crucial to identify the factors that regulate the growth of CSCs in cancer cells. CLDN6, for example, is a receptor for the hepatitis Cvirus (HCV). It has been shown that it promotes EMT and increases proliferation of hepatoma cell lines.

In a recent study, a HEC-1B cell line was used to screen CLDN6 expression in HEC293T cells. Our results revealed that HEC-1-B cells expressed significantly more CLDN6 protein than normal human ESC. This is a significant finding for clinical trials. However, more research is needed to confirm this finding.

Claudins are essential for tight junctions in cells. The CLDN clan includes 24 members. Individual expression patterns are unique to each member. It is not normal for CLDN6/Claudin6 to be expressed in cancer tissues. Claudin proteins can be described as transmembrane, transmembrane proteins. They form two extracellular Loops and a Cytoplasmic N-terminus. They regulate selective transport of ions within cells and act as paracellular barriers.